GILD vs ZBH
Gilead Sciences vs Zimmer Biomet — AI-powered side-by-side comparison
GILD
Gilead Sciences
64
Buy
VS
| Metric | GILD | ZBH |
|---|
| AI Score |
64
|
67
|
| Price |
$133.10
|
$97.77
|
| P/E Ratio |
-51.23×
|
23.38×
|
| ROE |
37.5%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
79.6%
|
69.9%
|
| Debt / Equity |
0.21×
|
0.59×
|
| Dividend Yield |
2.4%
|
1.0%
|
| RSI (14) |
54.4
|
58.9
|
| Beta |
0.336
|
0.462
|
| Expected Upside |
+18.2%
|
+1.2%
|
AI Committee View
Current Innellis committee reasoning for GILD versus ZBH.
ZBH leads by 3 points.
ZBH scores 67/100 (Buy) versus GILD at 64/100 (Buy).
GILD Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
ZBH Committee View
80% agreement
5 analysts
The primary driver is price-to-book of 1.4x is a discount to asset value. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
- Risk/reward is unfavorable: 11.2% downside vs 1.2% upside.